Jefferies Financial Group Comments on Immunocore Holdings plc’s FY2024 Earnings (NASDAQ:IMCR)

Immunocore Holdings plc (NASDAQ:IMCR – Get Rating) – Investment analysts at Jefferies Financial Group issued their FY2024 earnings per share (EPS) estimates for shares of Immunocore in a report issued on Sunday, January 22nd. Jefferies Financial Group analyst M. Yee expects that the company will post earnings of ($0.02) per share for the year. The consensus estimate for Immunocore’s current full-year earnings is ($0.54) per share.

A number of other research analysts also recently commented on the company. HC Wainwright upped their price objective on Immunocore from $80.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, November 21st. Barclays began coverage on Immunocore in a research note on Wednesday, November 30th. They set an “overweight” rating and a $80.00 price objective for the company. Morgan Stanley increased their price target on Immunocore from $72.00 to $79.00 and gave the stock an “overweight” rating in a research note on Thursday, November 10th. Finally, The Goldman Sachs Group raised Immunocore from a “neutral” rating to a “buy” rating and increased their price target for the stock from $33.00 to $80.00 in a research note on Friday, December 16th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $79.13.

Immunocore Price Performance

Shares of IMCR opened at $59.94 on Tuesday. The company has a market cap of $2.64 billion, a P/E ratio of -33.92 and a beta of 0.55. The stock has a fifty day moving average price of $59.28 and a 200 day moving average price of $53.03. The company has a debt-to-equity ratio of 0.25, a current ratio of 5.23 and a quick ratio of 5.21. Immunocore has a 12 month low of $20.02 and a 12 month high of $69.06.

Immunocore (NASDAQ:IMCR – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.40. The firm had revenue of $48.52 million during the quarter, compared to the consensus estimate of $37.73 million. Immunocore had a negative return on equity of 29.53% and a negative net margin of 59.17%.

Institutional Trading of Immunocore

Institutional investors have recently modified their holdings of the company. Dalton Investments LLC acquired a new stake in shares of Immunocore in the second quarter valued at $373,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Immunocore by 20.7% in the third quarter. Cubist Systematic Strategies LLC now owns 50,688 shares of the company’s stock valued at $2,379,000 after buying an additional 8,679 shares during the period. State Street Corp acquired a new stake in shares of Immunocore in the second quarter valued at $442,000. Renaissance Technologies LLC lifted its holdings in shares of Immunocore by 597.3% in the second quarter. Renaissance Technologies LLC now owns 50,900 shares of the company’s stock valued at $1,899,000 after buying an additional 43,600 shares during the period. Finally, Virtus ETF Advisers LLC lifted its holdings in shares of Immunocore by 63.2% in the second quarter. Virtus ETF Advisers LLC now owns 8,513 shares of the company’s stock valued at $318,000 after buying an additional 3,297 shares during the period. Institutional investors and hedge funds own 65.11% of the company’s stock.

Immunocore Company Profile

(Get Rating)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.